Catalog

Filter By

Top sellers

Special products

Slim figure

Slim figure

Manicure tools

Oli-oly

Подкатегории

Active filters

Mimpara 30MG
€318.40
Mimpara 60MG
€622.50
Mimpara 90MG
€784.10
Eligard 22.5MG
€458.70
Zevalin, 1.6 mg / ml
€18,850.00
Zometa ,4MG/100ML
€262.22
Omnitrope 15MG/1.5ML
Omnitrope 5MG/1.5ML
Estramon 30/95 µg
Estramon 50
€28.60
JANSSEN,Darzalex (Daratumumab) ,100 mg / 5ml, 1pcs
Eligard 45MG, 1 pcs
LITAK, 2MG/ML  5 ML
€584.97
Novothyral 75
€38.90
Elonva 100/0,5 ml
Elonva 150/0,5 ml
€817.70
Norditropin FLE 10MG
ESTRIFAM 2MG
€29.80
Zaltrap, 4 ml
€622.45
Zaltrap, 8 ml
€1,043.65

Semisynthetic antitumor agent of plant origin, obtained by chemical synthesis from natural raw materials - European yew needles (Taxus baccata). White or almost white powder, highly lipophilic and practically insoluble in water. The molecular weight of 861.9.

Semisynthetic antitumor agent of plant origin, obtained by chemical synthesis from natural raw materials - European yew needles (Taxus baccata). White or almost white powder, highly lipophilic and practically insoluble in water. The molecular weight of 861.9.

€318.40
€622.50
€784.10

Bone resorption inhibitor, bisphosphonate. Clodronic acid belongs to the group of bisphosphonates and is an analogue of natural pyrophosphate. Bisphosphonates have a high affinity for the mineral components of bone tissue. The main mechanism of action of clodronic acid is the suppression of the activity of osteoclasts and the decrease in bone resorption mediated by them.

prescription

Manufacturer AMGEN GMBH

The package with the drug in the form for parenteral administration should be stored in a dark place and out of the reach of children at a temperature of no higher than 30 ° C. The shelf life of lyophilized powder for solution preparation is 3 years.

on prescription

Manufacturer ASPEN

Adjuvant therapy for early hormone-positive breast cancer in postmenopausal women;

treatment of advanced breast cancer in postmenopausal women;

adjuvant therapy of early hormone-positive breast cancer in postmenopausal women after tamoxifen therapy for 2-3 years.

on prescription

Manufacturer ASTRAZENECA

The drug is a medicine that suppresses the effects of male sex hormone (testosterone) (non-steroidal antiandrogen).

Used to treat locally advanced prostate cancer and a high risk of disease progression.

The drug is a medicine that suppresses the effects of male sex hormone (testosterone) (non-steroidal antiandrogen).

Used to treat locally advanced prostate cancer and a high risk of disease progression.

€458.70
€18,850.00

treatment of recurrent or refractory CD20-positive indolent B-cell non-Hodgkin lymphoma in adult patients;

consolidation therapy after achieving remission in previously untreated patients with follicular lymphoma.

Kisplyx (Kisplyx) is indicated in combination with everolimus for the treatment of adult patients with renal cell carcinoma (PAC) after one previous vascular endothelial growth factor (VEGF) -targeted therapy.

Kisplyx (Kisplyx) is indicated in combination with everolimus for the treatment of adult patients with renal cell carcinoma (PAC) after one previous vascular endothelial growth factor (VEGF) -targeted therapy.

€262.22

The active substance in the drug is called zoledronic acid and is a representative of a group of substances called bisphosphonates. Zoledronic acid works by binding to bones and slowing down the speed of bone remodeling.

Idelalisib (idelalisib) is used to treat relapsing chronic lymphocytic leukemia, relapsing follicular non-Hodgkin B-cell lymphoma, and small cell lymphocytic lymphoma. Sidelig is used in combination with rituximab (rituximab).

€28.60

1 ml of concentrate contains: active substance: daratumumab - 20 mg; excipients: glacial acetic acid - 0.186 mg, sodium acetate trihydrate - 2.967 mg, sodium chloride - 3.506 mg, mannitol - 25.500 mg, polysorbate-20 - 0.400 mg, water for injection - up to 1.0 ml

The multicomponent composition regimens: osteogenic sarcoma, uterine sarcoma, lymphosarcoma, embryonal rhabdomyosarcoma, and pleural mesothelioma of the peritoneum, carcinoid tumors (including bronchogenic carcinoma, small cell lung cancer, thyroid cancer), pheochromocytoma, insulinoma, neuroblastoma, CNS tumor (glioma).

The multicomponent composition regimens: osteogenic sarcoma, uterine sarcoma, lymphosarcoma, embryonal rhabdomyosarcoma, and pleural mesothelioma of the peritoneum, carcinoid tumors (including bronchogenic carcinoma, small cell lung cancer, thyroid cancer), pheochromocytoma, insulinoma, neuroblastoma, CNS tumor (glioma).

€584.97

Litak is intended for the treatment of hairy cell leukemia. Litak solution is indicated as a second-line drug for the treatment of patients with recurrent or non-treatable lymphoproliferative diseases of low malignancy, such as follicular and diffuse non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Valdenström macroglobulinemia.

€38.90
€817.70

Kaitruda is the brightest representative of the monoclonal antibody group. Numerous clinical studies, practical experience with Keitruda, reviews of oncologists and patients suggest the uniqueness of this drug. Its feature is the ability to obtain favorable results even in the treatment of metastatic forms of malignant tumors

Zikadia has been developed for the treatment of non-small cell lung cancer, which has positive anaplastic lymphoma kinase with the ineffectiveness of other methods. The positive effect was confirmed after a series of trials on living patients.

In August 2017, the EU approved Novartis AG's Kisqali (ribocyclib) as the first line of treatment for breast cancer.

In August 2017, the EU approved Novartis AG's Kisqali (ribocyclib) as the first line of treatment for breast cancer.

€29.80

When using the drug, even in low doses, a slight increase in serum LH and FSH levels is observed, which is typical for drugs of this pharmacological group and probably develops according to the feedback principle at the pituitary level: a decrease in estrogen concentration stimulates the secretion of gonadotropins in the pituitary gland as well postmenopausal women.

on prescription

Manufacturer PFIZER

intoxication with folic acid antagonists (methotrexate, trimethoprim, pyrimethamine);

prevention of the toxic effects of methotrexate when used in high and high doses;

colorectal cancer (as part of complex therapy with fluorouracil)

Lymphoblastic leukemia, soft tissue sarcoma, osteogenic sarcoma, Ewing's sarcoma, breast cancer, thyroid cancer, Wilms tumor, neuroblastoma, bladder cancer, stomach cancer, ovarian cancer, lymphogranulomatosis, non-Hodgkin lymphoma, trophoblastic tumors.

€622.45

Concentrate for solution for infusion, 100 mg / 4 ml and 200 mg / 8 ml

Description

Transparent colorless or pale yellow liquid, free from mechanical impurities.

€1,043.65

Concentrate for solution for infusion, 100 mg / 4 ml and 200 mg / 8 ml

Description

Transparent colorless or pale yellow liquid, free from mechanical impurities.

Patients with lymphoma and multiple myeloma to enhance the mobilization of hematopoietic stem cells into the peripheral bloodstream to collect them and subsequent autotransplantation in combination with G-CSF